Transforming knowledge and clinical practice in eating disorders: the past decade through the lens of the Journal of Eating Disorders Authors: Stephen Touyz, Phillipa Hay Published: 2025 Many may remember the year 2013 as the year that Nelson Mandela died, and DSM − 5 was published. In the same year without pomp and ceremony, in a somewhat inauspicious manner, the world’s first open access journal in the field of eating disorders was launched and Journal of Eating Disorders remains the only Gold open access journal in the field of eating disorders to this day. At the time it was somewhat bold and courageous as then open access publishing was the exception rather than the norm and print journals reigned supreme. The field of eating disorders was no exception and was led by the International Journal of Eating Disorders and the European Eating Disorder Review as well as other highly regarded journals. Compared to these print journals, the Journal of Eating Disorders had (and continues to have) the challenge for authors to pay a significant Article Processing Charge upon the publication of their manuscript. It has taken time for both researchers and clinicians alike to appreciate the benefits of open access publishing with regards to its universal visibility and the retention of copyright by authors. Teachers, politicians, high school students, journalists, caregivers, those with lived experience and clinicians to name but only a few, can at a keystroke view and download all the very latest editorials, research, scholarly reviews, case reports and more. If ever there was a time in our history for the important dissemination of knowledge on eating disorders to all who desire it, it is surely now. So, what has changed in the past 12 years since the Journal of Eating Disorders came into existence? For one, the sheer proliferation of published material. Not unlike the Roman goddess of abundance and prosperity, Abundantia, depicted by Peter Paul Rubens, whose harp is overflowing with fruit, our harp overflows with publications on eating disorders. It is interesting to reflect on the content and to remind our readers of the papers that appeared in the very first edition of our Journal as well as the first editorial we (ST, PH) published as co-founding Editors-in -Chief [1]. Some of the early and highly cited papers included the “Cognitive -interpersonal maintenance model of anorexia nervosa revisited: a summary of the evidence for cognitive, socio-emotional and interpersonal predisposing and perpetuating factors” [2]. In this paper Treasure and Schmidt described the evidence-base relating to this model which yet attracts a great deal of interest to this day. Another seminal paper was that by Steinglass and Walsh [3] entitled a “Neurobiological model of the persistence of anorexia nervosa.” Neurobiological models are now receiving much attention in the current literature with novel neuromodulation treatments coming into play as well as psychedelics and how these may affect clinical outcome especially in those with severe and enduring anorexia nervosa (SE-AN). A further highly cited paper was by Pike and Dunn [4] entitled “The rise of eating disorders in Asia: a review”. Cultural diversity and the need to ensure that novel treatments are more culturally diverse is gaining widespread attention in contemporary debate. The Journal has also been awarding annual prizes for the best paper award since 2013, starting with Wade and Tiggemann [5] in the Senior category and Zwickert and Rieger [6] in the Early Career category. Over the past decade our knowledge base for these disorders has expanded considerably leading to effective interventions for adults, adolescents and children [7, 8]. Further, those with a more severe and enduring eating disorder (SEED) have finally been recognised and newer emerging treatments better tailored to their specific needs are gaining increasing attention and now constitutes part of the mainstream literature on AN. The Journal has had two Collections addressing longstanding forms of illness, in 2022 [9] and 2024/5 [10]. ST penned the first draft of this Editorial after visiting the excavation of the ancient city of Ephesus. Constructed in the 10th century BC, one can only marvel at the ingenuity of the architects of that time. Parliament buildings, shopping malls, an agora for leisure and business, an amphitheatre seating 25,000 patrons as well as flushing toilets and much more. These visionary talents are there for all to see. We in the field of eating disorders, especially when it relates to anorexia nervosa, need to embrace a bold agenda moving forward (not unlike those Roman architects and engineers of yesteryear) and the time has well and truly come to reconceptualise this complex illness. Gone are the days when we can continue to cling to the existing zeitgeist. At the 2025 European Council on Eating Disorders Congress in Budapest, several seminal papers made a valiant attempt to show how anorexia nervosa was comorbid with much of psychiatry. It is time to acknowledge that a deep dive into the phenomenology of anorexia nervosa is urgently needed which we believe will show it to be a highly complex psychiatric disorder as recognised by Lasegue nearly 150 years ago and exemplified in the paper by Cobbaert et al. “Neurodivergence, intersectionality, and eating disorders: a lived experience-led narrative review” [11]. The Journal has a recent Collection to stimulate and further an understanding of personalised medicine, taking all the psychiatric features ever present in anorexia nervosa into account, that may well lead to improved outcomes [12]. The zeitgeist is indeed “a changin”. With rTMS, psilocybin, ketamine and deep brain stimulation now gaining traction amongst clinicians and researchers alike, the years ahead look full of promise but much more is needed (see another recent Collection on psychedelics [13]). There can be no doubt that Artificial Intelligence will have a profound effect on our field. The Journal will be launching a Collection on this topic in 2026 with the hope of shedding light on how it can best serve eating disorder research and clinical practice. Look out for Collections in 2026 also on Diversity and Evidence reviews. In only a relatively short space of time, the Journal of Eating Disorders has gone from no impact factor at inception to 4.5 today, which in 2025 is the highest of any journal in the field of eating disorders. This would not have been possible without the dedication and commitment of a very hardworking Editorial Board. To you all, goes our heart-felt thanks and gratitude. A special word of thanks must go to Sara Ho, who served as our senior editorial assistant from day one and continues to keep an ever -watchful eye on the daily activities of the Journal. We are also grateful to Kristine Lamar who attends to all the correspondence relating to the Journal as well as Elina Zorina and dedicated teams working on our Collections and the team in Research Integrity and Resolutions, Springer Nature Research Integrity Group. Our first 12 years have delivered much but the task is not yet complete. The years ahead promise both interesting challenges and well-deserved rewards. To all of our colleagues, who have chosen to publish their work in the Journal, we thank you for your ongoing support as we continuously strive to innovate and further improve on all aspects of the Journal. We look forward to receiving both your feedback and future manuscripts. Acknowledgements Not applicable. Biographies Stephen Touyz Receives royalties from Hogrefe and Huber, BioMed Central, Taylor and Francis and McGraw Hill. He was a consultant to Takeda Pharmaceuticals and has provided a commissioned report to the Victorian Department of Health. Phillipa Hay Has received sessional fees from the Therapeutic Guidelines publication and the Health Education and Training Institute (HETI, NSW), and royalties/honoraria from Hogrefe and Huber, McGraw Hill Education, Blackwell Scientific Publications, BioMed Central, and PLOS Medicine. She has prepared a report under contract for Takeda (formerly Shire) Pharmaceuticals regarding binge eating disorder (July 2017) and was a consultant to Takeda Pharmaceuticals and to Tryptamine Pharmaceuticals Authors’ contributions ST conceived and wrote the first draft. PH edited drafts and submitted the final version. Funding None received. Data availability Not applicable. Declarations Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Competing Interests PH and ST are Editor in Chief of the Journal of Eating Disorders. Author PH has received sessional fees from the Therapeutic Guidelines publication and the Health Education and Training Institute (HETI, NSW), and royalties/honoraria from Hogrefe and Huber, McGraw Hill Education, Blackwell Scientific Publications, BioMed Central, and PLOS Medicine. She has prepared a report under contract for Takeda (formerly Shire) Pharmaceuticals regarding binge eating disorder (July 2017) and was a consultant to Takeda Pharmaceuticals and to Tryptamine Pharmaceuticals Author ST receives royalties from Hogrefe and Huber, BioMed Central, Taylor and Francis and McGraw Hill. He was a consultant to Takeda Pharmaceuticals and has provided a commissioned report to the Victorian Department of Health. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement Not applicable.